Evidence map›Paper›PMID 31123282›Full record

ArticleScientific reports2019

BRAF inhibition sensitizes melanoma cells to α-amanitin via decreased RNA polymerase II assembly.

Lukas Frischknecht, Christian Britschgi, Patricia Galliker, Yann Christinat, Anton Vichalkovski, Matthias Gstaiger, Werner J Kovacs, Wilhelm Krek

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Lukas FrischknechtInstitute of Molecular Health Sciences, ETH Zurich, 8093, Zurich, Switzerland.
Christian BritschgiInstitute of Molecular Health Sciences, ETH Zurich, 8093, Zurich, Switzerland.
Patricia GallikerInstitute of Molecular Health Sciences, ETH Zurich, 8093, Zurich, Switzerland.
Yann ChristinatInstitute of Molecular Health Sciences, ETH Zurich, 8093, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-4977-1362
Anton VichalkovskiInstitute of Molecular Systems Biology, ETH Zurich, 8093, Zurich, Switzerland.
Matthias GstaigerInstitute of Molecular Systems Biology, ETH Zurich, 8093, Zurich, Switzerland.
Werner J KovacsInstitute of Molecular Health Sciences, ETH Zurich, 8093, Zurich, Switzerland. werner.kovacs@biol.ethz.ch.ORCID http://orcid.org/0000-0002-4440-4344
Wilhelm KrekInstitute of Molecular Health Sciences, ETH Zurich, 8093, Zurich, Switzerland.
ETH Zurich · CHUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the great success of small molecule inhibitors in the treatment of patients with BRAF

Indexed as

Alpha-AmanitinApoptosisCell DeathCell Line, TumorHumansMelanomaNucleic Acid Synthesis InhibitorsProto-Oncogene Proteins B-rafRNA Polymerase IISignal TransductionAlpha-AmanitinBRAF protein, humanNucleic Acid Synthesis InhibitorsProto-Oncogene Proteins B-rafRNA Polymerase II

Identifiers

PMID31123282
PMCPMC6533289
OpenAlexW2945048453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.